Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism.
about
Tumor metastasis to boneInactivation of IL11 signaling causes craniosynostosis, delayed tooth eruption, and supernumerary teethBone density, structure, and strength in juvenile idiopathic arthritis: importance of disease severity and muscle deficitsOsteoimmunology: interactions of the bone and immune systemLessons from the Bone Chapter of the Malaysian Aging Men StudyPaget's disease of bone: an osteoimmunological disorder?Osteoimmunology and the influence of pro-inflammatory cytokines on osteoclastsComputational modeling of interactions between multiple myeloma and the bone microenvironmentOsteocyte Alterations Induce Osteoclastogenesis in an In Vitro Model of Gaucher DiseaseRutile and titanium particles differentially affect the production of osteoblastic local factors.Isoflavones are safe compounds for therapeutical applications - evaluation of in vitro data.Up-Regulation of RANK Expression via ERK1/2 by Insulin Contributes to the Enhancement of Osteoclast Differentiation.IL-1β promotes TGF-β1 and IL-2 dependent Foxp3 expression in regulatory T cells.Bone metastasis: mechanisms and therapeutic opportunities.Interleukin-6 and rheumatic diseases.Cytokine-mediated bone destruction in rheumatoid arthritis.gp130 at the nexus of inflammation, autoimmunity, and cancer.IL-11 produced by breast cancer cells augments osteoclastogenesis by sustaining the pool of osteoclast progenitor cells.Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activityChronic Obstructive Pulmonary Disease, inflammation and co-morbidity--a common inflammatory phenotype?Peroxiredoxin II negatively regulates lipopolysaccharide-induced osteoclast formation and bone loss via JNK and STAT3Radiographic emphysema predicts low bone mineral density in a tobacco-exposed cohort.Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies.Breast Cancer: Rank Ligand Inhibition.Denosumab for the treatment of bone metastases in breast cancer: evidence and opinionExpression of FcRL4 defines a pro-inflammatory, RANKL-producing B cell subset in rheumatoid arthritis.New insights into the pathophysiology and management of bone disease in multiple myeloma.Differential expression of immunologic proteins in gingiva after socket preservation in mini pigs.Active immunization with Tocilizumab mimotopes induces specific immune responses.The relationship between osteoclastogenic and anti-osteoclastogenic pro-inflammatory cytokines differs in human osteoporotic and osteoarthritic bone tissues.Disseminated prostate cancer cells can instruct hematopoietic stem and progenitor cells to regulate bone phenotype.The treatment of nonunions with application of BMP-7 increases the expression pattern for angiogenic and inflammable cytokines: a matched pair analysis.The role of osteoblast cells in the pathogenesis of unicameral bone cysts.Morphoproteomics provides support for TGF-β pathway signaling in the osteoclastogenesis and immune dysregulation of osteolytic Langerhans cell histiocytosis.The role of the receptor activator of nuclear factor-kappaB ligand/osteoprotegerin cytokine system in primary hyperparathyroidism.Expression and Presence of OPG and RANKL mRNA and Protein in Human Periodontal Ligament with Orthodontic Force.Interleukin-6: discovery of a pleiotropic cytokine.Malignant melanoma and bone resorption.Increased osteoclastic activity in acute Charcot's osteoarthropathy: the role of receptor activator of nuclear factor-kappaB ligand.Rheumatoid and pyrophosphate arthritis synovial fibroblasts induce osteoclastogenesis independently of RANKL, TNF and IL-6.
P2860
Q21195416-2E7B6F52-BBE5-4A3D-AE03-1983BC5685ECQ24312711-08084333-0D3F-46AE-9D57-3B9834899B15Q24653333-347B5B04-6AB5-4EE7-845F-67FA28E3E183Q24655113-22868FC7-2FBD-49CE-BE26-304B0C001942Q26745567-FE7E7AF7-012D-4F27-B438-B0C43DEEEFBAQ26796458-3D8698AF-2ECA-44C9-AD61-B7B9078F9F9EQ26828486-CDA4D729-3510-4424-BCB0-8A664482B144Q28477867-EA56B803-AA02-4C8C-A677-64F91D0D8FEDQ28817148-BEF75EC5-D371-4810-9222-2C1A37497041Q33289750-064E1B5B-C4F2-4355-951D-992A9EDD9D33Q33480555-16AC81D9-6E64-4934-A7EF-D03BC5BC19E9Q33775139-C49C49CA-15F9-45BF-A1C9-EFC9994328D2Q33968156-1A5586F6-A182-4E05-B288-5EFDA0E77961Q34025195-05624D3E-FCEB-4A05-9409-81466B5A14C3Q34160235-22DCC039-31B8-4129-A277-F9A227458DD0Q34252489-BD0D4D25-B335-433F-A043-123E6250EFB0Q34378756-884B2F1C-42CD-4F6B-BAB5-A3A4C9CFEC35Q34545945-030FF36E-B4FC-4F9F-B824-C62C9CFA2B3DQ34675956-35F92B70-3490-4506-A8C0-3B28EC1EEB56Q34684222-C53EA704-FB46-40EA-A69B-6904F3FF57CBQ34729815-962C08D2-3172-4842-877B-6F20AF6571C4Q34914760-C1728DA1-3333-4B02-835D-AA3998D68561Q35003674-9D5F312A-CA06-434C-BFA5-9CB292E0C5BDQ35095558-93309873-3410-4C7F-97FD-EFD9242F67F8Q35205280-29D27945-DC99-4156-9032-B6D11F6B7F53Q35350935-CBEC2214-1903-46D0-AC58-B52EBCE65203Q35591086-83DBEBAE-9D23-4AB5-9264-A13A9E75AE22Q35596723-AD629CC9-68BA-44AB-9598-DA3E71844E86Q35649177-C05B01A2-B793-482D-93DB-22677C2B238EQ35838186-E77FA180-18F2-43C5-9B77-2ADC6575DF98Q35840465-2815CEE0-4ACE-4C51-977B-8385F6B5152DQ36153143-4CFAF9E3-6627-4559-A3A4-108A7F1ABF1AQ36183290-0B68CC6F-BFE4-4402-9032-68CD9E50F9E9Q36196768-29AF116A-10C1-4195-B96D-CBD471D3CC10Q36494408-21CCABD1-A490-489D-BB72-A1A061B1E1A2Q36504036-25BD8BC6-A814-41C4-9164-9A12281089EFQ36561156-7E8F03FC-CBC4-4EE6-A088-824B6226076EQ36614173-F4837F7E-6949-4B35-BA5A-C3EF965038F0Q36617148-6CD5E3D4-4466-4628-9F76-1F86E9F523AFQ36670711-C47A7F12-9723-4ADC-A000-5F5078E81415
P2860
Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Interleukin-6 and interleukin- ...... a RANKL-independent mechanism.
@en
Interleukin-6 and interleukin- ...... a RANKL-independent mechanism.
@nl
type
label
Interleukin-6 and interleukin- ...... a RANKL-independent mechanism.
@en
Interleukin-6 and interleukin- ...... a RANKL-independent mechanism.
@nl
prefLabel
Interleukin-6 and interleukin- ...... a RANKL-independent mechanism.
@en
Interleukin-6 and interleukin- ...... a RANKL-independent mechanism.
@nl
P2093
P1433
P1476
Interleukin-6 and interleukin- ...... a RANKL-independent mechanism.
@en
P2093
P356
10.1016/S8756-3282(02)00915-8
P577
2003-01-01T00:00:00Z